AQST (Aquestive Therapeutics) Tariff Resilience Score: 6/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AQST Aquestive Therapeutics Inc AQST
49 GF Score
Price $5.16
GF Value $2.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aquestive Therapeutics Tariff Resilience Score?

Aquestive Therapeutics AQST -1.15% 49 Tariff Resilience Score is 6 as of Sep. 09, 2026. GuruFocus rates AQST with a GF Score™ of 49/100 and a GF Value™ of $2.37 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Aquestive Therapeutics ranks better than 91% on this metric.

Aquestive Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Aquestive Therapeutics has Aquestive Therapeutics Inc has moderate tariff exposure, with some reliance on international supply chains for pharmaceuticals. Industry-specific exemptions and strong pricing power help mitigate potential impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aquestive Therapeutics might have Average Resilient.

Aquestive Therapeutics  (NAS:AQST) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aquestive Therapeutics Tariff Resilience Score Related Terms

AQST vs TLRY, EOLS, IRWD: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aquestive Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Tariff Resilience Score falls into.


AQST
49GF Score
Aquestive Therapeutics Inc AQST
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Aquestive Therapeutics (AQST) has a Tariff Resilience Score of 6 as of Sep. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Aquestive Therapeutics ranks #92 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 9%.
Is Aquestive Therapeutics' Tariff Resilience Score too high?
Aquestive Therapeutics' current Tariff Resilience Score is 6. Based on the distribution chart, Aquestive Therapeutics ranks #92 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' Tariff Resilience Score compare to TLRY and EOLS?
According to the Drug Manufacturers industry distribution chart, Aquestive Therapeutics ranks #92 out of 1022 companies for Tariff Resilience Score. This places Aquestive Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Aquestive Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current Tariff Resilience Score is 6. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current Tariff Resilience Score is 6 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aquestive Therapeutics (AQST) Overvalued in 2026?

Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued. The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37. GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.

Key valuation signals for AQST:

  • Tariff Resilience Score: 6
  • GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aquestive Therapeutics Business Description

Address 30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score

Get the complete analysis for AQST

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.16
Price
$2.37
GF Value